UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Journal of clinical oncology, 2021-07, Vol.39 (20), p.JCO2003488-2303

2021

Volltextzugriff (PDF)

Targeting cyclin D1 for high risk myelodysplastic syndromes

Leukemia research, 2012-08, Vol.36 (8), p.964-965

Mundle, Suneel D

2012

Volltextzugriff (PDF)

Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role

Critical reviews in oncology/hematology, 2013-04, Vol.86 (1), p.15-22

2013

Volltextzugriff (PDF)

Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2014-12, Vol.19 (12), p.1231-1240

2014

Volltextzugriff (PDF)

Evolving intricacies and implications of E2F1 regulation

The FASEB journal, 2003-04, Vol.17 (6), p.569-574

2003

Volltextzugriff (PDF)

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part II

Journal of theoretical biology, 2019-01, Vol.460, p.37-55

2019

Volltextzugriff (PDF)

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

European urology, 2022-02, Vol.81 (2), p.184-192

2022

Volltextzugriff (PDF)

Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer

BJU international, 2024-07, Vol.134 (1), p.96-102

2024

Volltextzugriff (PDF)

A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients

World journal of urology, 2023-12, Vol.41 (12), p.3535-3542

2023

Volltextzugriff (PDF)

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

European journal of cancer (1990), 2023-11, Vol.193, p.113290-113290, Article 113290

2023

Volltextzugriff (PDF)

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

British journal of cancer, 2024-01, Vol.130 (1), p.73-81

2024

Volltextzugriff (PDF)

Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Prostate cancer and prostatic diseases, 2023-12, Vol.26 (4), p.813-813

2023

Volltextzugriff (PDF)

Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Prostate cancer and prostatic diseases, 2023-03, Vol.26 (1), p.156-161

2023

Volltextzugriff (PDF)

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Future oncology (London, England), 2024-03, Vol.20 (10), p.563-578

2024

Volltextzugriff (PDF)

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

European urology oncology, 2024-08, Vol.7 (4), p.844-852

2024

Volltextzugriff (PDF)

Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review

European urology oncology, 2024-05

2024

Volltextzugriff (PDF)

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part I

Mathematical biosciences, 2016-04, Vol.274, p.83-93

2016

Volltextzugriff (PDF)

Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow

International journal of hematology, 2004-08, Vol.80 (2), p.146-154

2004

Volltextzugriff (PDF)

Advances in erythropoietic growth factor therapy for myelodysplastic syndromes

Expert opinion on biological therapy, 2006-11, Vol.6 (11), p.1099-1104

Mundle, Suneel D

2006

Volltextzugriff (PDF)

Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes

Future oncology (London, England), 2007-08, Vol.3 (4), p.397-403

Mundle, Suneel D

2007

Volltextzugriff (PDF)

MP60-02 REAL WORLD TREATMENT SEQUENCE AND SURVIVAL IN LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER AND POSTPROGRESSION DISEASE STATES

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Par-4: A common facilitator/enhancer of extrinsic and intrinsic pathways of apoptosis

Leukemia research, 2006-05, Vol.30 (5), p.515-517

Mundle, Suneel D.

2006

Volltextzugriff (PDF)

Defining the dynamics of self-assembled Fas-receptor activation

Trends in immunology, 2002-04, Vol.23 (4), p.187-194

2002

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(83)

Sprache

Englisch
(83)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(55)
Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Male
(28)
Myelodysplastic Syndromes - Pathology
(27)
Apoptosis
(23)
Hematology
(19)
Biological And Medical Sciences
(17)
Oncology
(17)
Female
(16)
Medical Sciences
(16)
Myelodysplastic Syndrome
(15)
Aged
(14)
Bone Marrow Cells - Pathology
(12)
Hematologic And Hematopoietic Diseases
(12)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(12)
Middle Aged
(12)
Myelodysplastic Syndromes
(12)
Animals
(10)
Bone Marrow - Pathology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Targeting cyclin D1 for high risk myelodysplastic syndromes

Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer

Evolving intricacies and implications of E2F1 regulation

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part II

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer

A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review

Mathematical modeling of bone marrow – peripheral blood dynamics in the disease state based on current emerging paradigms, part I

Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow

Advances in erythropoietic growth factor therapy for myelodysplastic syndromes

Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes

MP60-02 REAL WORLD TREATMENT SEQUENCE AND SURVIVAL IN LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER AND POSTPROGRESSION DISEASE STATES

Par-4: A common facilitator/enhancer of extrinsic and intrinsic pathways of apoptosis

Defining the dynamics of self-assembled Fas-receptor activation

Suchergebnisse filtern